Primary hyperparathyroidism is an endocrine disorder characterized by autonomous PTH secretion by the parathyroid glands that is not adequately suppressed by ionized calcium. The typical pathophysiological result is PTH-mediated hypercalcemia, often associated with relatively low serum phosphate and increased calcium flux between bone, kidney and the extracellular compartment. Clinically, in most cases the disease no longer presents as the “classic” picture of osteitis fibrosa cystica, but rather as a broad spectrum that includes asymptomatic forms, paucisymptomatic forms with subtle findings and symptomatic forms dominated by nephrolithiasis, reduced bone mineral density and renal complications.
The key concept is that although the primary physiological function of PTH is to stabilize calcium levels, when it is produced inappropriately it becomes a driver of bone remodeling and renal calcium load. Clinical risk therefore depends not only on the absolute serum calcium level, but also on the duration of exposure and the vulnerability of target organs, particularly the kidneys and skeleton. This framework explains why primary hyperparathyroidism is now a central topic in the preventive management of osteoporosis and nephrolithiasis, as well as in surgical endocrinology.
Primary hyperparathyroidism is one of the most common endocrine disorders in the adult population, with prevalence increasing with age and a higher frequency in women, particularly after menopause. Its epidemiology has been profoundly shaped by the routine inclusion of serum calcium in blood chemistry panels. Many diagnoses are made after the incidental detection of mild hypercalcemia, before obvious clinical signs develop. This has reduced the proportion of severe presentations with advanced skeletal involvement and increased the importance of assessing clinically “silent” target-organ damage, such as asymptomatic stones or unrecognized vertebral fractures.
Some of the epidemiological variability depends on the concept of “mild disease” and on the diagnostic criteria used. Some patients have only mildly elevated serum calcium and moderately increased PTH, but still face a meaningful risk of progression over time, particularly when the biochemical abnormality is stable and persistent. At the same time, increasing attention has been paid to normocalcemic primary hyperparathyroidism, in which serum calcium remains repeatedly normal but PTH is persistently elevated after rigorous exclusion of secondary causes. The true frequency of this entity varies widely between studies and clinical settings because it depends critically on the quality of the exclusion of vitamin D deficiency, renal impairment, malabsorption, medications and hypercalciuria, all of which may sustain an adaptive increase in PTH.
Risk factors do not correspond to a single environmental determinant, but include age and sex, family history and, in a minority of cases, genetic predisposition. Although rare, syndromic forms are clinically relevant because hyperparathyroidism may be the first manifestation of a more complex disorder, with implications for surgical timing, the risk of multifocal disease and follow-up. Certain medications also significantly influence the likelihood of PTH-mediated hypercalcemia or modify its clinical expression. Lithium is the most important example because it may alter the parathyroid suppression set-point and promote hypercalcemia with inappropriate PTH secretion. Thiazide diuretics, by increasing renal calcium reabsorption, may worsen hypercalcemia and unmask pre-existing disease.
The clinical impact of primary hyperparathyroidism also depends on coexisting comorbidities. Reduced glomerular filtration increases the risk of complications and complicates the interpretation of certain mineral metabolism parameters. Osteoporosis, frailty, a history of fractures and increased fall risk all amplify the clinical consequences of chronic PTH elevation because they accelerate bone loss and reduce functional reserve. Similarly, a history of nephrolithiasis or a lithogenic profile that favors precipitation of calcium salts increases the likelihood of renal manifestations, even when serum calcium is only mildly elevated.
In summary, the modern epidemiology of primary hyperparathyroidism is that of a disease often detected early, in which risk is defined more by target-organ damage and individual vulnerability than by symptom intensity. This perspective justifies a thorough diagnostic pathway and risk stratification that already anticipates the decision between definitive treatment and surveillance.
Under physiological conditions, the parathyroid glands regulate PTH secretion in response to minimal changes in ionized calcium through the calcium-sensing receptor (CaSR). When calcium levels fall, PTH secretion increases and produces rapid effects on the kidneys and bone, while indirectly stimulating intestinal calcium absorption by increasing renal synthesis of calcitriol. In primary hyperparathyroidism, this system loses its fine control. PTH secretion becomes inappropriate relative to serum calcium, and hypercalcemia is no longer able to suppress hormonal output effectively. The biochemical phenotype is therefore characterized by elevated or inadequately suppressed PTH, often with increased serum calcium and relatively low serum phosphate due to increased phosphaturia.
From an etiological perspective, the most common cause is a single parathyroid adenoma, followed by multigland hyperplasia. Parathyroid carcinoma is rare but clinically important because it may cause severe, recurrent hypercalcemia with markedly elevated PTH levels and a high risk of systemic complications. In a proportion of cases, primary hyperparathyroidism occurs within genetic syndromes in which parathyroid proliferation is associated with other endocrinopathies or tumors, with implications for the extent of surgery and the likelihood of multifocal disease. Pharmacological modulation of the CaSR, as occurs with lithium, may also increase the suppression set-point and sustain hypercalcemia with inappropriate PTH secretion, producing a biochemical picture that may mimic “classic” primary disease.
The pathophysiology of excess PTH mainly involves bone and kidney. In bone, PTH increases remodeling through the RANKL pathway and osteoclast activation mediated by stromal and osteoblastic cells. In persistent disease, this causes loss of bone mass, with a predilection for cortical bone, and increases fracture risk. In historically more advanced forms, excessive turnover may produce focal lesions and bone pain, whereas in milder modern presentations the damage is often clinically silent and detectable through densitometry, vertebral assessment and a history of nontraumatic fractures.
In the kidney, PTH increases calcium reabsorption in the distal tubule and reduces phosphate reabsorption in the proximal tubule, thereby promoting phosphaturia. However, in primary hyperparathyroidism, hypercalcemia increases the filtered calcium load and may cause hypercalciuria in many patients, with a risk of stone formation and nephrocalcinosis. Chronic hypercalcemia may also impair urinary concentrating capacity, promoting polyuria and relative dehydration and creating a cycle that further increases serum calcium and predisposes to acute worsening when fluid intake is reduced.
At the systemic level, PTH-mediated hypercalcemia may cause neurocognitive, gastrointestinal and neuromuscular symptoms, which are often nonspecific but clinically relevant. The clinical presentation depends on the rate of increase in serum calcium and on target-organ reserve. A rapid rise tends to produce more obvious symptoms, whereas a slow increase may be tolerated but cause cumulative renal and skeletal damage. This explains why diagnosis and management cannot be based solely on symptom severity and must instead integrate pathophysiology with assessment of target-organ damage.
Finally, primary hyperparathyroidism interacts with vitamin D status and the calcitriol axis. Vitamin D deficiency may further increase PTH and worsen skeletal involvement, whereas correction must be carefully titrated and monitored because it may alter serum and urinary calcium. This bidirectional relationship makes assessment of 25-OH vitamin D essential and requires PTH and calcium to be interpreted as components of a dynamic system rather than as isolated values.
The clinical presentation of primary hyperparathyroidism is now often subtle and variable. Many patients are diagnosed after the incidental detection of mild hypercalcemia, but a meaningful proportion develop renal or skeletal manifestations before the diagnosis is established. The disease should therefore be regarded as a continuum, ranging from asymptomatic forms with a potential risk of progression to symptomatic forms in which complications are already the main clinical expression.
On clinical history, symptoms related to hypercalcemia may include increased thirst and polyuria, constipation, nausea, reduced appetite and loss of energy. Neurocognitive symptoms may include difficulty concentrating, mental “fog”, irritability and sleep disturbances, all of which may be attributed to other causes unless an endocrine and metabolic disorder is considered. Neuromuscular involvement may present as proximal weakness and easy fatigability, particularly when vitamin D deficiency, physical inactivity or frailty coexist.
Renal manifestations are often more specific. Episodes of renal colic, a history of recurrent nephrolithiasis, hematuria or complicated urinary tract infections may lead to the diagnosis. Even in the absence of symptoms, the presence of “silent” stones or nephrocalcinosis on imaging has major clinical significance because it identifies target-organ damage and changes the therapeutic strategy. Some patients develop a reduced glomerular filtration rate or progressive deterioration of renal function that may be attributed solely to other comorbidities unless correctly interpreted.
Skeletal manifestations may be equally relevant. The disease may be detected during the evaluation of osteoporosis, fragility fractures or clinically silent vertebral fractures. A history of back pain, height loss or low-energy fractures should prompt assessment of calcium and PTH metabolism because isolated anti-osteoporotic treatment may be insufficient if the primary cause of increased bone turnover remains active.
The physical examination is frequently nonspecific, but should assess for signs of dehydration, reduced muscle tone and strength, bone pain and indirect signs of complicated nephrolithiasis. In more severe forms, hypercalcemia may be associated with psychomotor slowing and confusion, particularly in older adults or patients with reduced neurological reserve. When serum calcium is markedly elevated or symptoms progress rapidly, the presentation may indicate a risk of hypercalcemic crisis, requiring urgent stabilization before definitive correction of the underlying cause.
Overall, the clinical manifestations of primary hyperparathyroidism should be interpreted as the integrated expression of hypercalcemia and target-organ damage. The presence of nonspecific symptoms should not reduce clinical vigilance because the true prognostic determinant is the combination of duration of exposure and effects on the kidneys and skeleton, which are often measurable even when the patient reports few symptoms.
Primary hyperparathyroidism should first be suspected in the presence of hypercalcemia with elevated or inadequately suppressed PTH. In a physiological system, increased serum calcium should suppress PTH. When this does not occur, a PTH-mediated mechanism becomes the leading hypothesis. High-normal serum calcium with persistently elevated PTH may also be suggestive, particularly when associated with target-organ damage or increased urinary calcium.
Suspicion should be high in patients with recurrent nephrolithiasis, nephrocalcinosis or silent stones detected on imaging because these findings are compatible with a chronic renal calcium load. Assessment is likewise indicated when osteoporosis, fragility fractures, clinically silent vertebral fractures or accelerated loss of bone mineral density are identified, particularly when the findings are not explained by other factors or when the response to standard treatment is suboptimal.
Another clinical scenario involves nonspecific symptoms compatible with hypercalcemia, including polyuria, thirst, constipation, nausea, fatigue and cognitive difficulties. When persistent and associated with even moderately elevated serum calcium, these symptoms should prompt PTH measurement and targeted assessment. Suspicion should be strengthened when predisposing factors are present, such as the use of lithium or thiazides, a family history of calcium disorders or a personal history of endocrinopathies suggesting a possible syndromic form.
When PTH is elevated and serum calcium is normal, normocalcemic primary hyperparathyroidism may be considered, but only after rigorous exclusion of secondary hyperparathyroidism. In particular, vitamin D deficiency, reduced renal function, malabsorption, medications and hypercalciuria may sustain an adaptive increase in PTH and mimic primary disease. This scenario requires longitudinal assessment, with repeated measurements under stable conditions and after correction of the most common confounding variables.
Finally, when serum calcium is markedly elevated and the patient presents with dehydration, vomiting, altered mental status or rapid clinical deterioration, suspicion should include severe PTH-mediated hypercalcemia and a possible risk of hypercalcemic crisis. In these cases, clinical stabilization is the priority, but PTH should be measured early because it guides identification of the cause and the timing of definitive treatment.
The diagnosis of primary hyperparathyroidism is based on demonstrating elevated or inappropriately normal PTH in the presence of hypercalcemia, after repeated confirmation of the values and assessment of factors that influence serum calcium. Total serum calcium should be interpreted in relation to albumin, and in uncertain cases or complex clinical settings the measurement of ionized calcium may be particularly informative. PTH should be measured with a reliable assay and interpreted according to physiological principles. Nonsuppressed PTH in the presence of hypercalcemia is a cardinal sign of PTH-mediated disease.
The initial assessment should include phosphate, creatinine with estimated glomerular filtration rate and 25-OH vitamin D. Vitamin D is essential both for correct interpretation of PTH and for estimation of skeletal risk because deficiency may worsen hyperparathyroidism and increase the severity of bone involvement. Renal function is equally important. A significant reduction in glomerular filtration alters mineral metabolism and requires caution before attributing PTH elevation to primary disease, particularly when serum calcium is not clearly elevated.
Diagnostic assessment of primary hyperparathyroidism
A decisive diagnostic step is distinguishing primary hyperparathyroidism from familial hypocalciuric hypercalcemia because both conditions may present with hypercalcemia and nonsuppressed PTH. Twenty-four-hour urinary calcium and interpretation of the overall biochemical profile, together with family history and stability of the condition over time, reduce the risk of misdiagnosis and inappropriate surgery. In patients with stones or suspected hypercalciuria, assessment of lithogenic risk is also useful for guiding prevention and follow-up, irrespective of the surgical indication.
When serum calcium is normal and PTH is elevated, the diagnosis of normocalcemic primary hyperparathyroidism requires rigorous exclusion of secondary causes and confirmation that the abnormality persists over time. Correction of vitamin D deficiency, verification of calcium intake and assessment of renal function and malabsorption are essential steps. Certain medications may also increase PTH or alter serum and urinary calcium, requiring cautious evaluation and, when possible, reassessment after optimization of the clinical context.
Parathyroid imaging is not required to establish the diagnosis. Ultrasonography, scintigraphy and techniques such as 4D CT are preoperative localization tools used after a decision for surgical treatment has already been made. Performing imaging before establishing a solid biochemical diagnosis increases the risk of incidental findings and misleading interpretations. In forms suspicious for parathyroid carcinoma, the severity of hypercalcemia and PTH elevation, together with clinical and radiological findings, supports referral for specialist surgery with specific oncological objectives. Even in this setting, however, the diagnostic process begins with biochemical assessment and evaluation of clinical severity.
Classification of primary hyperparathyroidism is useful because it links presentation and risk to different therapeutic strategies. The first distinction concerns the biochemical phenotype: classic hypercalcemic forms and normocalcemic forms with persistently elevated PTH after exclusion of secondary causes. This distinction is not merely descriptive because the natural history of normocalcemic disease is less certain and the decision to operate requires stricter assessment of target-organ damage and progression.
A second classification is clinical and distinguishes asymptomatic from symptomatic disease. Symptomatic forms include nephrolithiasis, nephrocalcinosis, fragility fractures, significant skeletal involvement and symptoms of hypercalcemia that impair quality of life. In asymptomatic disease, severity is not defined by the absence of symptoms, but by the presence or absence of clinically silent target-organ damage and by the likelihood of progression, which depends on serum calcium, renal function, bone density and clinical history.
Severity also includes the degree of hypercalcemia and its change over time. Mild, stable hypercalcemia may be managed with surveillance in selected patients, whereas more marked or progressive hypercalcemia increases the risk of complications and favors definitive treatment. Significant hypercalciuria and stone formation, even when clinically silent, are markers of severity because they indicate established renal involvement. From a skeletal perspective, reduced bone mineral density and vertebral fractures, including clinically silent fractures, identify a level of risk that cannot be reduced to serum calcium alone.
Multigland and syndromic forms represent a separate category because they carry a higher probability of recurrence and require more structured follow-up. In these settings, the surgical approach and surveillance strategy differ from those used for a single adenoma because the objective is not only to resolve hypercalcemia, but also to reduce the risk of persistent or recurrent disease and manage the broader endocrine context.
Finally, classification should include the possibility of parathyroid carcinoma when the disease is particularly severe. Markedly elevated serum calcium and PTH, especially when accompanied by a palpable mass or signs of invasion, require specialist management because the surgical strategy and follow-up differ substantially from those used for benign disease. Although rare, this possibility influences the safety of management in the most severe presentations.
The aims of treatment for primary hyperparathyroidism are to normalize serum calcium, reduce excess PTH and prevent or limit renal and skeletal complications. Parathyroidectomy is the definitive treatment and, when indicated, is highly effective in correcting hypercalcemia and improving bone mineral density over time. It is indicated in all symptomatic patients and in many asymptomatic patients with target-organ risk criteria because surveillance in these cases carries a greater probability of progression and adverse events. Surgery requires preoperative planning with localization studies and an appropriate operative strategy, particularly to maximize efficacy and reduce the risk of persistent disease.
The rationale for surgery in asymptomatic disease is based on objective parameters defining renal and skeletal risk. The presence of nephrolithiasis or nephrocalcinosis, reduced glomerular filtration, serum calcium persistently above the expected threshold, significant reduction in bone mineral density or vertebral fractures identifies patients in whom the benefit of definitive treatment is more evident. The decision should also consider age and the probability of prolonged exposure to hypercalcemia because a younger patient with even moderate risk factors may accumulate damage over time if definitive treatment is not performed.
When surgery is not possible or not indicated, medical therapy is directed primarily at controlling hypercalcemia and protecting the skeleton. Calcimimetics reduce serum calcium by increasing CaSR sensitivity and are useful in patients with persistent hypercalcemia who are not surgical candidates or who are awaiting surgery, particularly when the clinical priority is to reduce symptoms and acute risk. From a skeletal perspective, antiresorptive agents may improve bone mineral density in selected patients, but they do not remove the underlying endocrine cause and require integrated assessment of renal risk, urinary calcium and fracture profile.
Management of vitamin D is a critical issue. Correction of deficiency is important for reducing parathyroid stimulation and improving skeletal health, but it should be performed with monitoring because it may increase serum and urinary calcium in some patients. Calcium intake also requires a balanced approach. Excessive restriction may increase PTH and worsen bone health, whereas excessive intake may promote hypercalciuria and stone formation. The clinical objective is to maintain a balance that limits progression of skeletal damage without increasing renal risk.
In severe or symptomatic hypercalcemia, the priority is stabilization with hydration and measures that rapidly lower serum calcium according to severity and clinical context. Definitive treatment should not be delayed in these settings. Severe primary hyperparathyroidism may progress to acute complications and renal deterioration, making management more complex. When parathyroid carcinoma is suspected, surgery should be planned in a specialist setting because the objective is en bloc disease control, reducing the risk of local recurrence and recurrent hypercalcemia.
In summary, treatment of primary hyperparathyroidism is centered on definitive correction when indicated and on reduction of target-organ risk when surgery is not feasible. The optimal strategy derives from integration of biochemical findings, renal imaging and skeletal assessment, with an approach that prioritizes prevention of irreversible damage rather than symptom control alone.
Follow-up of primary hyperparathyroidism aims to verify biochemical stability, prevent complications and monitor the renal and skeletal course. After parathyroidectomy, early surveillance includes serum calcium and PTH to confirm resolution and identify transient hypocalcemia or possible hungry bone syndrome in patients with high preoperative bone turnover. At a later stage, monitoring aims to document skeletal recovery and identify persistent or recurrent disease, particularly in multigland or syndromic forms.
In patients managed conservatively or with medical therapy, the frequency of follow-up should be structured. Reassessment of calcium, PTH, phosphate, renal function and 25-OH vitamin D allows progression or instability to be identified and the treatment plan to be adjusted. Serum calcium determines the risk of both symptoms and acute deterioration during dehydration, whereas PTH helps estimate endocrine activity and its effect on bone turnover. Renal function should be monitored over time because the combination of hypercalcemia and hypercalciuria may impair glomerular filtration and because worsening renal function also changes the interpretation of mineral metabolism.
Renal follow-up includes clinical surveillance for recurrent colic and imaging when appropriate, particularly in patients with a history of nephrolithiasis or previously documented silent stones. A 24-hour urine collection, repeated at selected intervals, may be useful for quantifying urinary calcium and establishing individualized stone-prevention strategies that integrate hydration, diet and, when necessary, pharmacological interventions consistent with the lithogenic profile.
Skeletal follow-up requires bone densitometry at intervals appropriate to the level of risk and, when indicated, vertebral assessment to identify clinically silent fractures. Progressive recovery of bone density is expected after surgery, but the rate depends on age, vitamin D status, physical activity, protein intake and the presence of other causes of osteoporosis. In patients who are not operated on, skeletal follow-up is one of the main tools for identifying progression and reconsidering the indication for definitive treatment.
Finally, continuity of care includes education on the signs of hypercalcemia and on the management of conditions that may precipitate acute worsening, such as dehydration, vomiting and reduced fluid intake. Effective follow-up reduces the interval between biological progression and clinical decision-making, preventing an initially mild condition from evolving into recurrent nephrolithiasis or advanced skeletal fragility.
The prognosis of primary hyperparathyroidism is generally favorable when the diagnosis is correct and treatment is appropriate to the risk profile. When indicated, parathyroidectomy normalizes serum calcium in the large majority of patients and reduces chronic exposure to PTH-mediated stimulation that drives bone loss and renal complications. However, the reversibility of complications depends on disease duration. Skeletal recovery is gradual and may require years, whereas renal complications may persist when independent lithogenic factors are present or when nephrocalcinosis has already reduced functional renal reserve.
The main complications are nephrolithiasis and nephrocalcinosis, with a risk of recurrent colic, complicated infections and, in some cases, deterioration of glomerular filtration. The risk derives from the chronic filtered calcium load and possible hypercalciuria, as well as from reduced urinary concentrating capacity in some patients with persistent hypercalcemia. Even when serum calcium is only moderately elevated, prolonged exposure may cause cumulative damage, making renal assessment a central component of prognosis.
From a skeletal perspective, increased turnover and cortical bone loss increase the risk of osteoporosis and fractures, including clinically silent vertebral fractures that may present as back pain or height loss. Myopathy and muscle frailty, when present, increase the risk of falls and amplify fracture risk, creating a cycle involving weakness, physical inactivity and loss of bone mass. Correction of the disease improves bone density and strength over time, but requires support through nutrition, physical activity and correction of vitamin status.
Acute complications are related to severe hypercalcemia, which may cause dehydration, acute deterioration of renal function and neurocognitive changes progressing to severe hypercalcemic syndromes. In older or frail patients, even moderate increases may precipitate rapid decline in the setting of reduced fluid intake or intercurrent illness. Prevention of dehydration and timely management of acute exacerbations are therefore concrete prognostic factors.
Treatment-related complications depend on the chosen approach. After surgery, transient hypocalcemia and hungry bone syndrome may occur, particularly in patients with high bone turnover, while complications related to neck surgery are less common. Medical therapy with calcimimetics requires monitoring to prevent hypocalcemia and adjust doses according to serum calcium and tolerability, whereas skeletal therapies should be selected with consideration of renal function and the overall mineral metabolism profile. In the rare case of parathyroid carcinoma, prognosis depends on local disease control and prevention of recurrence, with hypercalcemia representing the main determinant of morbidity. A dedicated specialist pathway is therefore essential.
Overall, primary hyperparathyroidism is often controllable and, when treated correctly, is associated with favorable outcomes. Prognosis depends on the prompt identification of target-organ damage and on the ability to choose between definitive treatment and risk-based surveillance, avoiding management guided solely by symptom intensity.